The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review
The meeting of the expert council concerning the application of new highly selective inhibitor of Brutons tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma was held in Moscow on April 21, 2021. The leading Russian experts in the field of oncohema...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
IP Habib O.N.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/51e15491eb424cc3a2503cf65691ad49 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:51e15491eb424cc3a2503cf65691ad49 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:51e15491eb424cc3a2503cf65691ad492021-11-30T16:55:01ZThe Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review1815-14341815-144210.26442/18151434.2021.2.200936https://doaj.org/article/51e15491eb424cc3a2503cf65691ad492021-08-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/77851/58448https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442The meeting of the expert council concerning the application of new highly selective inhibitor of Brutons tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma was held in Moscow on April 21, 2021. The leading Russian experts in the field of oncohematology took part in the meeting.Kamil D. KaplanovIP Habib O.N.articlemantle cell lymphomabruton’s tyrosine kinase inhibitorzanubrutinibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 2, Pp 253-255 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
RU |
| topic |
mantle cell lymphoma bruton’s tyrosine kinase inhibitor zanubrutinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
mantle cell lymphoma bruton’s tyrosine kinase inhibitor zanubrutinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Kamil D. Kaplanov The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review |
| description |
The meeting of the expert council concerning the application of new highly selective inhibitor of Brutons tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma was held in Moscow on April 21, 2021. The leading Russian experts in the field of oncohematology took part in the meeting. |
| format |
article |
| author |
Kamil D. Kaplanov |
| author_facet |
Kamil D. Kaplanov |
| author_sort |
Kamil D. Kaplanov |
| title |
The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review |
| title_short |
The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review |
| title_full |
The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review |
| title_fullStr |
The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review |
| title_full_unstemmed |
The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review |
| title_sort |
russian expert council on the application of new highly selective inhibitor of bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. event review |
| publisher |
IP Habib O.N. |
| publishDate |
2021 |
| url |
https://doaj.org/article/51e15491eb424cc3a2503cf65691ad49 |
| work_keys_str_mv |
AT kamildkaplanov therussianexpertcouncilontheapplicationofnewhighlyselectiveinhibitorofbrutonstyrosinekinasezanubrutinibinthetreatmentofpatientswithrelapsedrefractorymantlecelllymphomaeventreview AT kamildkaplanov russianexpertcouncilontheapplicationofnewhighlyselectiveinhibitorofbrutonstyrosinekinasezanubrutinibinthetreatmentofpatientswithrelapsedrefractorymantlecelllymphomaeventreview |
| _version_ |
1718406444537085952 |